Vaccinating against Helicobacter pylori infection

Nature Reviews Gastroenterology and Hepatology

Volumn 8, Issue 3, 2011, Pages 133-140

  Czinn, Steven J ^a   Blanchard, Thomas ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; ESCHERICHIA COLI VACCINE; HELICOBACTER PYLORI VACCINE; PLACEBO; UREASE;

ABSENCE OF SIDE EFFECTS; ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTIBODY RESPONSE; BACTERIAL LOAD; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SPECIFICITY; ERADICATION THERAPY; GASTRITIS; HELICOBACTER INFECTION; HUMAN; INFECTION COMPLICATION; INFECTION PREVENTION; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TENESMUS; VACCINATION;

ANIMALS; BACTERIAL LOAD; BACTERIAL VACCINES; COST-BENEFIT ANALYSIS; DISEASE MODELS, ANIMAL; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICE; TREATMENT OUTCOME;

EID: 79952454960     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2011.1     Document Type: Review

References (75)

1. Eurogast Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet 341, 1359-1362 (1993).
2. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. J. Am. Med. Assn. 272, 65-69 (1994).
3. Parsonnet, J. et al. Helicobcter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 325, 1127-1131 (1991).
4. Warren, J. R. & Marshall, B. J. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1, 1273-1275 (1983)
5. WHO. in IARC monographs on the carcogenic risks to humans. 61, 177-241 (IARC, Lyon, 1994).
6. Franceschi, F. & Gasbarrini, A. Helicobacter pylori and extragastric diseases. Best Pract. Res. Clin. Gastroenterol. 21, 325-334 (2007). (Pubitemid 46421908)
7. Graham, D. Y et al. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 100, 1495-1501 (1991).
8. Kruszon-Moran, D. & McQuillan, G. M. Seroprevalence of six infectious diseases among adults in the United States by race/ethnicity: data from the third national health and nutrition examination survey. Adv. Data 352, 1-9 (2005).
9. Luther, J. & Kao, J. Y Considering global vaccination against Helicobacter pylori. South. Med. J. 103, 185-186 (2010).
10. Frenck, R. W. Jr & Clemens, J. Helicobacter pylori in the developing world. Microbes Infect. 8, 705-713 (2003).
11. Parsonnet, J. What is the Helicobacter pylori global reinfection rate? Can. J. Gastroenterol. 17 (Suppl. B), 46-48 (2003).
12. Gisbert, J. The recurrence of Helicobacter pylori infection: incidence and variables influencing it A critical review. Am. J. Gastroenterol. 100, 2083-2099 (2005).
13. Rupnow, M. F., Shachter, R. D., Owens, D. K. & Parsonnet, J. Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine 20, 879-885 (2001). (Pubitemid 34015829)
14. Svennerholm, A. M. & Lundgren, A. Progress in vaccine development against Helicobacter pylori. FEMS Immunol. Med. Microbiol. 50, 146-156 (2007). (Pubitemid 46918647)
15. Marshall, B. J. & Warren, J. R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1, 1311-1315 (1984).
16. Lee, A., Fox, J. G., Otto, G. & Murphy, J. A smal animal model of human Helicobacter pylori active chronic gastritis. Gastroenterology 99, 1315-1323 (1990). (Pubitemid 20381865)
17. Lee, A. et al. A standardised mouse model of Helicobacter pylori infection. Introducing the Sydney strain. Gastroenterology 112, 1386-1397 (1997). (Pubitemid 27157555)
18. st edn Ch. 9 (eds Sutton, P & Mitchell, H.) 167-190 (CABI, Wallingford, 2010).
19. Corthesy-Theulaz, I. et al. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology 109, 115-121 (1995).
20. Doidge, C et al. Therapeutic immunisation against Helicobacter infection. Lancet 343, 914-915 (1994). (Pubitemid 24113641)
21. Sutton, P et al. Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies. Immunol. Cell. Biol. 78, 28-30 (2000). (Pubitemid 30090986)
22. Chen, M. et al. Immunisation against gastric infection with Helicobacter species: first step in the prophylaxis of gastric cancer? Zentralbl. Bakteriol. 280, 155-165 (1993).
23. Czinn, S. J., Cai, A. & Nedrud, J. G. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA mmunization. Vaccine 11, 637-642 (1993). (Pubitemid 23142620)
24. Ghiara, P et al. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect. Immun. 65, 4996-5002 (1997). (Pubitemid 27513542)
25. Lee, C K. et al. Oral Immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J. Infect. Dis. 172, 161-172 (1995).
26. Marchetti, M. et al. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 267, 1655-1658 (1995).
27. Michetti, P et al. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology 107, 1002-1011 (1994).
28. Weltzin, R. et al. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine 15, 370-376 (1997). (Pubitemid 27157692)
29. Eisenberg, J. C et al. Protective efficacy of anti-Helicobacter pylori immunity following systemic mmunization of neonatal mice. Infect. Immun. 71, 1820-1827 (2003). (Pubitemid 36368711)
30. Gottwein, J. M. et al. Protective anti-Helicobacter mmunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic mmunization. J. Infect Dis. 184, 308-314 (2001). (Pubitemid 32662177)
31. Guy, B. et al. Systemic immunization with urease protects mice against Helicobacter pylori infection. Vaccine 16, 850-856 (1998). (Pubitemid 28238673)
32. Delyria, E. S., Redline, R. W. & Blanchard, T. G. vaccination of mice against H. pylori induces a strong Th-17 response and immunity that is neutrophil dependent. Gastroenterology 136, 247-256 (2008).
33. Velin, D. et al. Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model. Gastroenterology 136, 2237-2246 (2009).
34. Eaton, K. A., Mefford, M. & Thevenot, T. The role of T cell subsets and cytokines in the pathogenesis of Helicobacter pylori gastritis in mice. J. Immunol. 166, 7456-7461 (2001). (Pubitemid 32525623)
35. Velin, D., Bachmann, D., Bouzourene, H. & Michetti, P Mast cells are critical mediators of vaccine-induced Helicobacter clearance in the mouse model. Gastroenterology 129, 142-155 (2005). (Pubitemid 41002051)
36. Ermak, T. H. et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J. Exp. Med. 188, 2277-2288 (1998). (Pubitemid 29028500)
37. Blanchard, T. G. et al. Antibody-independent protective mucosal immunity to gastric helicobacter infection in mice. Cell. Immunol. 191, 74-80 (1999). (Pubitemid 29054969)
38. Cuenca, R. et al. Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets. Gastroenterology 110, 1770-1775 (1996). (Pubitemid 26169214)
39. Guy, B. et al. Mucosal, Systemic, or combined therapeutic immunizations in cynomolgus monkeys naturally infected with Gastrospirillum hominis-like organisms. Vaccine Research 6, 141-150 (1997). (Pubitemid 28192882)
40. Dubois, A. et al. Immunization against natural Helicobacter pylori infection in nonhuman primates. Infect. Immun. 66, 4340-4346 (1998). (Pubitemid 28402710)
41. Lee, C K. et al. Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. Vaccine 17, 1493-1505 (1999). (Pubitemid 29138817)
42. Lee, C. K. et al. Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori. Vaccine 17, 3072-3082 (1999). (Pubitemid 29366987)
43. Eaton, K. A., Ringler, S. S. & Krakowka, S. vaccination of gnotobiotic piglets against Helicobacter pylori. J. Infect Dis. 178, 1399-1405 (1998).
44. Michetti, P et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116, 804-812 (1999). (Pubitemid 29153528)
45. Banerjee, S. et al. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 51, 634-640 (2002). (Pubitemid 35216848)
46. Sougioultzis, S. et al. Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine 21, 194-201 (2002). (Pubitemid 35346814)
47. Marchetti, M. et al. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 16, 33-37 (1998). (Pubitemid 27504801)
48. Summerton, N. A. et al. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 28, 1404-1411 (2010).
49. Kotloff, K. L. et al. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun. 69, 3581-3590 (2001). (Pubitemid 32493271)
50. Ferrero, R. L. et al. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc. Natl Acad. Sci. USA 92, 6499-6503 (1995).
51. Angelakopoulos, H. & Hohmann, E. L. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun. 68, 2135-2141 (2000). (Pubitemid 30164846)
52. DiPetrillo, M. D. et al. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 18, 449-459 (1999). (Pubitemid 29462601)
53. Bumann, D. et al. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 20, 845-852 (2001). (Pubitemid 34015824)
54. Metzger, W. G. et al. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 22, 2273-2277 (2004). (Pubitemid 38626066)
55. Aebischer, T et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut 57, 1065-1072 (2008).
56. Graham, D. Y et al. Challenge model for Helicobacter pylori infection in human volunteers. Gut 53, 1235-1243 (2004). (Pubitemid 39120104)
57. Sakaguchi, S. et al. Regulatory T cells: how do they suppress immune responses? Int. Immunol. 21, 1105-1111 (2009).
58. Rubtsov, Y P. et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28, 546-558 (2008).
59. Matsumoto, Y et al. Eradication of Helicobacter pylori and resolution of gastritis in the gastric mucosa of IL-10-deficient mice. Helicobacter 10, 407-415 (2005). (Pubitemid 41368699)
60. Raghavan, S. et al. Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice. Clin. Exp. Immunol. 132, 393-400 (2003). (Pubitemid 36713944)
61. Rad, R. et al. CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology 131, 525-537 (2006). (Pubitemid 44142446)
62. Anderson, K. M., Czinn, S. J., Redline, R. W. & Blanchard, T G. Induction of CTLA-4-mediated anergy contributes to persistent colonization in the murine model of gastric Helicobacter pylori infection. J. Immunol. 176, 5306-5313 (2006).
63. Blanchard, T G., Yu, F., Hsieh, C L. & Redline, R. W. Severe inflammation and reduced bacteria load in murine helicobacter infection caused by lack of phagocyte oxidase activity J. Infect. Dis. 187, 1609-1615 (2003). (Pubitemid 36578967)
64. Fan, X. J. et al. Gastric T lymphocyte responses to Helicobacter pylori in patients with H. pylori colonisation. Gut 35, 1379-1384 (1994).
65. Karttunen, R. Blood lymphocyte proliferation, cytokine secretion and appearance of T cells with activation surface markers in cultures with Helicobacter pylori. Comparison of the responses of subjects with and without antibodies to H. pylori. Clin. Exp. Immunol. 83, 396-400 (1991).
66. Karttunen, R. Helicobacter pylori induces lymphocyte activation in peripheral blood cultures. Clin. Exp. Immunol. 82, 485-488 (1990).
67. Karttunen, R., Karttunen, T., Ekre, H. P & MacDonald, T T Interferon gamma and interleukin 4 secreting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis. Gut 36, 341-345 (1995).
68. Sharma, S. A. et al. Humoral and cellular mmune recognition of Helicobacter pylori proteins are not concordant. Clin. Exp. Immunol. 97, 126-132 (1994). (Pubitemid 24244066)
69. Raghavan, S., Suri-Payer, E. & Holmgren, J. Antigen-specific in vitro suppression of murine Helicobacter pylori-reactive immunopathological T cells by CD4CD25 regulatory T cells. Scand. J. Immunol. 60, 82-88 (2004). (Pubitemid 38943054)
70. Harris, P R. Helicobacter pylori gastritis in children is associated with a regulatory T-cel response. Gastroenterology 134, 491-499 (2008). (Pubitemid 351173044)
71. Dooley, C P. et al. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N. Engl. J. Med. 321, 1562-1566 (1989). (Pubitemid 20008234)
72. Garhart, C A., Redline, R. W., Nedrud, J. G. & Czinn, S. J. Clearance of Helicobacter pylori infection and resolution of postimmunization gastritis in a kinetic study of prophylactically mmunized mice. Infect. Immun. 70, 3529-3538 (2002). (Pubitemid 34665989)
73. Malfertheiner, P et al. Safety and mmunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 135, 787-795 (2008).
74. Rossi, G. et al. Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity and efficacy Infect. Immun. 72, 3252-3259 (2004). (Pubitemid 38697746)
75. Sayi, A. et al. The CD4+ T cell-mediated IFN-gamma response to Helicobacter infection is essential for clearance and determines gastric cancer risk. J. Immunol. 182, 7085-7101 (2009).